Use of teriparatide in treatment of severe osteoporosis in geriatric practice: a clinical case review

Elderly and senile people are characterized by a high prevalence of osteoporosis, which, in turn, increases the risk of fractures, including the repeated ones. Fractures in osteoporosis are an extremely unfavorable complication of the disease, leading to catastrophic consequences in old age. The prevalence of osteoporotic fractures progressively increases with age. At present, the cumulative frequency of hip fractures in women over 80 is about 30%. The proportion of vertebral fractures in women older than 80 years is up to 40% of all vertebral osteoporotic fractures. Despite the tremendous successes achieved in the diagnosis and treatment of osteoporosis, the disease itself and related fractures remain a serious medical, economic and social problem. Prevention of recurrent fractures in geriatric patients is a system of preventive, rehabilitative and therapeutic measures aimed at reducing the risk of falls, choosing an effective therapy, and reducing the risk of recurring fractures. A serious problem in the treatment of osteoporosis in older people is the inefficiency of the antiresorptive therapy due to an age-related decrease in bone formation. There are frequent cases of a continuing decrease in bone density, the occurrence of repeated fractures during ongoing therapy of osteoporosis. Often the therapy of choice in this case is bone-anabolic therapy with teriparatide, which allows one to achieve good results in the accumulation of bone mineral density. In this article, we will present the clinical case of an elderly patient with severe osteoporosis, in which teriparatide became the drug of choice.

1. Cooper C, Campion G, Melton LJ 3rd. Hip fractures in the elderly: a world-wide projection. Osteoporos Int. 1992;2(6):285-289. DOI:10.1007/BF01623184

2. Grados F, Marcelli C, Dargent-Molina P, et al. Prevalence of vertebral fractures in French women older than 75 years from the EPIDOS study. Bone. 2004:34(2):362-367. DOI:10.1016/j.bone.2003.11.008

3. Российская ассоциация геронтологов и гериатров. Старческая астения. Клинические рекомендации. 2018. [Rossiyskaya assotsiatsiya gerontologov i geriatrov. Starcheskaya asteniya. Klinicheskie rekomendatsii. 2018. (In Russ.)]

4. Ткачева О.Н., Рунихина Н.К., Котовская Ю.В., и др. Ведение пациентов со старческой астенией в первичном звене здравоохранения. Учебное пособие для врачей. — М.; 2016. [Tkacheva ON, Runikhina NK, Kotovskaya YV, et al. Vedenie patsientov so starcheskoy asteniey v pervichnom zvene zdravookhraneniya. Uchebnoe posobie dlya vrachey. Moscow; 2016. (In Russ.)]

5. Ткачева О.Н., Рунихина Н.К., Котовская Ю.В., и др. Старческая астения: Что необходимо знать о ней врачу первичного звена? // РМЖ. — 2017. — Т. 25. — №25. — С. 1820-1822. [Tkacheva ON, Runikhina NK, Kotovskaya YV, et al. Senile asthenia: what must the primary care physician know about it? RMZh. 2017;25(25):1820-1822. (In Russ.)]

6. Gielen E, Verschueren S, O’Neill TW, et al. Musculoskeletal frailty: a geriatric syndrome at the core of fracture occurrence in older age. Calcif Tissue Int. 2012:91(3):161-177. DOI:10.1007/s00223-012-9622-5

7. Gielen E, Bergmann P, Bruyere O, et al. Osteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club. Calcif Tissue Int. 2017;101(2):111-131. DOI:10.1007/s00223-017-0266-3

8. Wilkins CH, Sheline YI, Roe CM, еt al. Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. Am J Geriatr Psychiatry. 2006; 14(12):1032-1040. DOI:10.1097/01.JGP.0000240986.74642.7c

9. Shamliyan T, Talley KM, Ramakrishnan R, Kane RL. Association of frailty with survival: a systematic literature review. Ageing Res Rev. 2012;12(2):719-736. DOI:10.1016/j.arr.2012.03.001

10. Cesari M, Prince M, Thiyagarajan JA, et al. Frailty: an emerging public health priority. J Am Med Dir Assoc. 2016:17(3):188-192. DOI:10.1016/j.jamda.2015.12.016

11. Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15(4):721-379. DOI:10.1359/jbmr.2000.15.4.721

12. Diez-Perez A, Adachi JD, Agnusdei D, et al. Treatment failure in osteoporosis. Osteoporos Int. 2012;23(12):2769-2774. DOI:10.1007/ s00198-012-2093-8

13. Dobnig H, Stepan JJ, Burr DB, et al. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate. J Bone Miner Res. 2009;24(12):1998-2006. DOI:10.1359/jbmr.090527

14. Holick MF, Siris ES, Binkley N, et al. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab. 2005;90(6):3215-3124. DOI:10.1210/jc.2004-2364

15. Boonen S, Marin F, Mellstrom D, et al. Safetyand efficacy of teriparatide in elderly women with established osteoporosis: boneanabolic therapy from a geriatric perspective. J Am Geriatr Soc. 2006;54(5):782-789. DOI:10.1111/j.1532-5415.2006.00695.x

16. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007;40(6):1434-1446. doi: https://doi/org/10.1016/j.bone.2007.03.017